Form 8-K Jazz Pharmaceuticals For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
November 6, 2019 11:26 AM ESTOppenheimer analyst Esther Rajavelu raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $179.00 (from $176.00) while maintaining a Outperform rating.
The analyst commented, "We update our JAZZ model following 3Q19 results that topped our estimates for both revenue (Xyrem beat) and adjusted earnings.... More
